Treatment options for patients who have antiphospholipid syndromes.
The antiphospholipid thrombosis syndrome, associated with anticardiolipin (aCL) or subgroup antibodies, can be divided into one of six subgroups (I-VI). There is little overlap (about 10% or less) between these subtypes, and patients usually conveniently fit into only one of these clinical types. Although there appears to be no correlation with the type, or titer, of aCL antibody and type of syndrome, the subclassification of thrombosis and aCL antibody patients into these groups is important from the therapy standpoint. This article also reviews the clinical presentations associated with each of these six subgroups.
Bick
Rodger L
RL
rbick@thrombosis.com
Baker
William F
WF
D017152:Antibodies, Antiphospholipid / Q000009:adverse effects / Q000145:classification / Q000187:drug effects*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
D017152:Antibodies, Antiphospholipid; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors